ArticleThe Lancet. Oncology2020

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

Robert C Doebele et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.